COVID vaccination and asthma exacerbation: might there be a link?
•Worldwide, the prevalence of asthma is high among teenagers and school children.•Monitoring adverse events following coronavirus disease 2019 (COVID-19) vaccination is important for practitioners.•There are plans for mass COVID-19 vaccination of teenagers and school children.•The effect of COVID-19...
Gespeichert in:
Veröffentlicht in: | International journal of infectious diseases 2021-11, Vol.112, p.243-246 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Worldwide, the prevalence of asthma is high among teenagers and school children.•Monitoring adverse events following coronavirus disease 2019 (COVID-19) vaccination is important for practitioners.•There are plans for mass COVID-19 vaccination of teenagers and school children.•The effect of COVID-19 vaccination on asthmatic individuals is unknown and unreported.•This article reports the first case of asthma exacerbation following COVID-19 vaccination.
There is ongoing debate regarding the role of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in asthma exacerbation, and its long-term impact on the lung function of individuals with asthma. In contrast, the potential impact of coronavirus disease 2019 (COVID-19) vaccination on asthma is entirely unexplored.
This study examined a challenging case of severe asthma exacerbation in a 28-year-old female following two doses of the mRNA-based vaccine BNT162b2 (Pfizer-BioNTech) at IRCCS Policlinico San Matteo in Pavia, Italy. The patient, a fourth-year resident at the hospital, was vaccinated in early 2021. She was an occasional smoker with a 10-year history of asthma and seasonal allergic rhinitis. She tested negative for SARS-CoV-2 on several molecular swabs and serology tests.
After receiving the second dose of vaccine, the patient started to experience worsening of respiratory symptoms. Following several episodes and a severe asthma attack, the patient required treatment with mepolizumab, a biologic drug (interleukin-5) antagonist monoclonal antibody.
This single case study is insufficient to draw conclusions about the association between asthma exacerbation and the COVID-19 vaccine. While the cause–effect link between vaccination against SARS-CoV-2 and worsening of asthmatic disease might only be suggested at present, this case is a valuable prompt for further investigation. This is particularly true from the perspective of mass vaccination of adolescents and children currently underway across the globe. |
---|---|
ISSN: | 1201-9712 1878-3511 1878-3511 |
DOI: | 10.1016/j.ijid.2021.09.026 |